In Weight-loss-only people, will Mounjaro be dangerous or harmful? Do they have higher chances of side effects because they don’t have diabetes? Isn’t this drug made just for diabetes patients? Why won’t it make them sick or give them blood sugar lows since they’re not diabetic patients trying to lower their blood sugar?

The blood sugar lowering activities of Mounjaro in the body happen in a glucose-dependent way. Meaning only when glucose is high does Mounjaro trigger the body to release more insulin to control it. GLP-1 Receptor Agonist drugs work to lower blood sugar by enhancing insulin secretion, and only enhances insulin secretion in a glucose-dependent manner. If a nondiabetic person is not suffering hyperglycemia, their blood sugar will not be lowered.


“GLP-1 metabolites inhibit hepatic glucose production, exert antioxidant cardio- and neuroprotective actions, reduce oxidative stress in vasculature and have both anti-apoptotic and proliferative effects in pancreatic β-cells, putatively by the modulation of mitochondrial functions. These findings have implications in energy homeostasis, obesity and its associated metabolic and cardiovascular complications as well as incretin-based therapies for the treatment of diabetes and obesity.”

GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products (paywall) 


“The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively.”
Tirzepatide Once Weekly for the Treatment of Obesity

July 2022, New England Journal of Medicine 


From ENDO 2021: Ushering in a New Era of Sustainable Weight Loss with Incretin-Based Therapies